Hepatitis C therapeutics: Current status and emerging strategies

Nature Reviews Drug Discovery

Volumn 1, Issue 11, 2002, Pages 867-881

  Tan, Seng Lai ^a   Pause, Arnim ^b   Shi, Yuguang ^a   Sonenberg, Nahum ^b  

^a ELI LILLY AND COMPANY   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUFERON ALPHA; ALPHA GLUCOSIDASE INHIBITOR; ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; BENZIMIDAZOLE; BETA1A INTERFERON; CASPASE INHIBITOR; CONSENSUS INTERFERON; HISTAMINE; INOSINATE DEHYDROGENASE; INTERLEUKIN 10; LEVOVIRIN; LIVER PROTECTIVE AGENT; MACROGOL; MERIMEPODIB; MIGLUSTAT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; OMNIFERON; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; HEPATITIS VACCINE;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHARMACEUTICS;

ANIMALS; BASE SEQUENCE; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; TECHNOLOGY, PHARMACEUTICAL; VIRAL HEPATITIS VACCINES;

EID: 0036835590     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd937     Document Type: Review

References (125)

1. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
2. Hoofnagle, J. H. Hepatitis C - the clinical spectrum of disease. Hepatology 26, S15-S20 (1997).
3. Memon, M. I. & Memon, M. A. Hepatitis C: an epidemiological review. J. Viral Hepatitis 9, 84-100 (2002).
4. Anonymous. Hepatitis C - global prevalence (update). World Health Org. Weekly Epidemiol. Rec. 75, 18-19 (2000).
5. Willems, M., Metselaar, H. J., Tilanus, H. W., Schalm, S. W. & de Man, R. A. Liver transplantation and hepatitis C. Transplant Int. 15, 61-72 (2002).
6. Pollard, R. B. Analogy of human immunodeficiency virus to hepatitis C virus: the human immunodeficiency model. Am. J. Med. 107, 41S-44S (1999).
7. Rehermann, B. Interaction between the hepatitis C virus and the immune system. Semin. Liv. Dis. 20, 127-141 (2000).
8. Di Bisceglie, A. M., McHutchinson, J. & Rice, C. M. New therapeutic strategies for hepatitis C. Hepatology 35, 224-231 (2002).
9. Wang, Q. M. & Heinz, B. A. Recent advances in prevention and treatment of hepatitis C virus infections. Prog. Drug Pes. 55, 1-32 (2000).
10. Dymock, B. W., Jones, P. S. & Wilson, F. X. Novel approaches to the treatment of hepatitis C virus infection. Antivir. Chem. Chemother. 11, 79-96 (2000).
11. Ideo, G. & Bellobuono, A. New therapies for the treatment of chronic hepatitis C. Curr. Pharm. Des. 8, 959-966 (2002).
12. Locarnini, S. A. & Bartholomeusz, A. Advances in hepatitis C: what is coming in the next 5 years? J. Gastroenterol. Hepatol. 17, 442-447 (2002).
13. Myles, D. C. Recent advances in the discovery of small molecule therapies for HCV. Curr. Opin. Drug Discov. Dev. 4, 411-416 (2001).
14. Bartenschlager, R. & Lohmann, V. Novel cell culture systems for the hepatitis C virus. Antiviral Res. 52, 1-17 (2001).
15. Mercer, D. F. et al. Hepatitis C virus replication in mice with chimeric human livers. Nature Med. 7, 927-933 (2001).
16. Ilan, E. et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185, 153-161 (2002).
17. Robertson, B. et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143, 2493-2503 (1998).
18. Rosenberg, S. Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. 313, 451-464 (2001).
19. Friebe, P., Lohmann, V., Krieger, N. & Bartenschlager, R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol. 75, 12047-12057 (2001).
20. Friebe, P. & Bartenschlager, R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J. Virol. 76, 5326-5338 (2002).
21. Reed, K. E. & Rice, C. M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Hep. C Viruses 242, 55-84 (2000).
22. Carrere-Kremer, S. et al. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J. Virol. 76, 3720-3730 (2002).
23. Walewski, J. L., Keller, T. R., Stump, D. D. & Branch, A. D. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA-A Pub. RNA Soc. 7, 710-721 (2001).
24. Xu, Z. M. et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20, 3840-3848 (2001).
25. Shirota, Y. et al. Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity. J. Biol. Chem. 277, 11149-11155 (2002).
26. Bartenschlager, R. & Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 81, 1631-1648 (2000).
27. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
28. Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57, 223-229 (1999).
29. Agnello V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96, 12766-12771 (1999).
30. Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103-107 (1998).
31. Bukh, J., Miller, R. H. & Purcell, R. H. Genetic heterogeneity of hepatitis C virus - quasispecies and genotypes. Semin. Liv. Dis. 15, 41-63 (1995).
32. Zein, N. N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13, 223-235 (2000).
33. Herion, D. & Hoofnagle, J. H. The interferon sensitivity determining region - all hepatitis C virus isolates are not the same. Hepatology 25, 769-771 (1997).
34. Tan, S. L. & Katze, M. G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284, 1-12 (2001).
35. Farci, P. & Purcell, R. H. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin. Liv. Dis. 20, 103-126 (2000).
36. Dammacco, F. et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin. Liv. Dis. 20, 143-157 (2000).
37. Hoofnagle, J. H. et al. Treatment of chronic non-A, non-B hepatitis with recombinant human α-interferon. A preliminary report. N. Engl. J. Med. 315, 1575-1578 (1986).
38. Scott, L. J. & Perry, C. M. Interferon-α2b plus ribavirin - a review of its use in the management of chronic hepatitis C. Drugs 62, 507-556 (2002).
39. Lau, J, Y. N., Tam, R. C., Liang, T. J. & Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35, 1002-1009 (2002).
40. Bekkering, F. C., Brouwer, J. T., Hansen, B. E. & Schalm, S. W. Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin. J. Hepatol. 34, 435-440 (2001).
41. Tsutsumi, M., Takada, A., Takase, S. & Sawada, M. Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis - a pilot study. J. Gastroenterol. Hepatol. 11, 1006-1011 (1996).
42. Komatsu, M. et al. Pilot study of ofloxacin and interferon-α combination therapy for chronic hepatitis C without sustained response to initial interferon administration. Can. J. Gastroenterol. 11, 507-511 (1997).
43. Moscarella, S. et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C - preliminary results. Liver 18, 366-369 (1998).
44. Brillanti, S., Levantesi, F., Masi, L., Foli, M. & Bolondi, L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 32, 630-634 (2000).
45. Zilly, M. et al. Triple antiviral re-therapy for chronic hepatitis C with interferon-α, ribavirin and amantadine in nonresponders to interferon-α and ribavirin. Eur. J. Med. Res. 7, 149-154 (2002).
46. Kozlowski, A., Charles, S. A. & Harris, J. M. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 15, 419-429 (2001).
47. Zeuzem, S. et al. PEGinterferon-α2a in patients with chronic hepatitis C. N. Engl. J. Med. 343, 1666-1672. (2000).
48. Heathcote, E. J. et al. PEG-interferon-α2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673-1680 (2000).
49. Manns, M. P. et al. PEG-interferon-α2b plus ribavirin compared with interferon-α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
50. Enomoto, M. et al. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-β treatment are predictive of long-term therapeutic response. J. Interferon Cytokine Res. 22, 389-395 (2002).
51. Barbaro, G. et al. Intravenous recombinant interferon-β versus interferon-α2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-α. Scand. J. Gastroenterol. 34, 928-933 (1999).
52. Kumashiro, R. et al. Interferon-γ brings additive anti-viral environment when combined with interferon-α in patients with chronic hepatitis C. Hepatol. Res. 22, 20-26 (2002).
53. Barbaro, G. & Barbarini, G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon-α2b and ribavirin in combination: an Italian pilot study. Eur. J. Gastroenterol. Hepatol. 14, 477-483 (2002).
54. Chang, C. C. et al. Evolution of a cytokine using DNA family shuffling. Nature Biotechnol. 17, 793-797 (1999).
55. Maier, I. & Wu, G. Y. Hepatitis C and HIV co-infection: a review. World J. Gastroenterol. 8, 577-579 (2002).
56. Falck-Ytter, Y. et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann. Intern. Med. 136, 288-292 (2002).
57. De Francesco, R. et al. Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Sem. Liv. Dis. 20, 69-83 (2000).
58. Darke, P. L., Jacobs, A. R., Waxman, L. & Kuo, L. C. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides - implications for control of viral processing. J. Biol. Chem. 274, 34511-34514 (1999).
59. Thibeault, D., Maurice, R., Pilote, L., Lamarre, D. & Pause, A. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus. J. Biol. Chem. 276, 46678-46684 (2001).
60. Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M. & Rice, C. M. A second hepatitis C virus-encoded proteinase. Proc. Natl Acad. Sci. USA 90, 10583-10587 (1993).
61. Hijikata, M. et al. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67, 4665-4675 (1993).
62. Whitney, M. et al. A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity. J. Biomol. Screening 7, 149-154 (2002).
63. Kolykhalov, A. A., Mihalik, K., Feinstone, S. M. & Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol. 74, 2046-2051 (2000).
64. Yao, N. H., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999).
65. Ingallinella, P. et al. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry 41, 5483-5492 (2002).
66. Zhang, R. M., Durkin, J. P. & Windsor, W. T. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg. Med. Chem. Lett. 12, 1005-1008 (2002).
67. Slater, M. J. Design and synthesis of pyrrolidine-5,5-translactams as novel inhibitors of hepatitis C virus protease. Antiviral Research - 15th International Conference, Prague, Czech Republic (2002).
68. Fukuda, K. et al. Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur. J. Biochem. 267, 3685-3694 (2000).
69. Kumar, P. K. R. et al. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237, 270-282 (1997).
70. Yao, N. H. et al. Structure of the hepatitis C virus RNA helicase domain. Nature Struct. Biol. 4, 463-467 (1997).
71. Kang, L. W. et al. Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein. Acta Crystallograph. D 54, 121-123 (1998).
72. Levin, M. K. & Patel, S. S. The helicase from hepatitis C virus is active as an oligomer. J. Biol. Chem. 274, 31839-31846 (1999).
73. Pang, P. S., Jankowsky, E., Planet, P. J. & Pyle, A. M. The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding. EMBO J. 21, 1168-1176 (2002).
74. Tanji, Y., Hijikata, M., Satoh, S., Kaneko, T. & Shimotohno, K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J. Virol. 69, 1575-1581 (1995).
75. Yang, S. H., Lee, C. G., Song, M. K. & Sung, Y. C. Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease. Virology 268, 132-140 (2000).
76. Kolykhalov, A. A. et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277, 570-574 (1997).
77. Leveque, V. J.-P. & Wang, Q. M. RNA-dependent RNA polymerase encoded by hepatitis C virus: biomedical applications. Cell Mol. Life Sci. 59, 909-919 (2002).
78. Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13039 (1999).
79. Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Struct. Biol. 6, 937-943 (1999).
80. Qin, W. P. et al. Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase. J. Biol. Chem. 277, 2132-2137 (2002).
81. Cheney, I. W. et al. Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology 297, 298-306 (2002).
82. De Francesco, R. Diketobutanoic acids as HCV Pol inhibitors, 7th International Meeting on Hepatitis C Virus and Related Viruses (Molecular Virology and Pathogenesis), Gold Coast, Queensland, Australia (2000).
83. Moradpour, D. et al. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277, 593-601 (2002).
84. Biroccio, A., Hamm, J., Incitti, I., De Francesco, R. & Tomei, L. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 76, 3688-3696 (2002).
85. Usman, N. & Blatt, L. R. M. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106, 1197-1202 (2000).
86. Macejak, D. G. et al. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 31, 769-776 (2000).
87. Zhang, H. et al. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV vaccinia virus recombinant. Antimicrob. Agents Chemother. 43, 347-353 (1999).
88. Brown-Driver, V., Eto, T., Lesnik, E., Anderson, K. P. & Hanecak, R. C. Inhibition of translation of hepatitis C virus RNA by 2′-modified antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 9, 145-154 (1999).
89. Witherell, G. ISIS-14803 (Isis Pharmaceuticals). Curr. Opin. Invest. Drugs 2, 1523-1529 (2001).
90. Lambot, M. et al. Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. J. Biol. Chem. 277, 20625-20630 (2002).
91. Wellnitz, S. et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J. Virol. 76, 1181-1193 (2002).
92. Tseng, C. T. K. & Klimpel, G. R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195, 43-49 (2002).
93. Crotta, S. et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195, 35-41 (2002).
94. Weiner, A. J. et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol. 75, 7142-7148 (2001).
95. Major, M. E. et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76, 6586-6595 (2002).
96. Bassett, S. E. et al. Protective immune response to hepatitis C virus In chimpanzees rechallenged following clearance of primary infection. Hepatology 33, 1479-1487 (2001).
97. Bukh, J., Forns, X., Emerson, S. U. & Purcell, R. H. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 44, 132-142 (2001).
98. Lechmann, M. & Liang, T. J. Vaccine development for hepatitis C. Semin. Liv. Dis. 20, 211-226 (2000).
99. Markland, W., McQuaid, T. J., Jain, J. & Kwong, A. D. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with α-interferon. Antimicrob. Agents Chemother. 44, 859-866 (2000).
100. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nature Rev. Drug Discov. 1, 65-75 (2002).
101. Block, T. M. et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med. 4, 610-614 (1998).
102. Mehta, A. et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 33, 1488-1495 (2001).
103. Zitzmann, N. et al. Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl Acad. Sci. USA 96, 11878-11882 (1999).
104. Durantel, D. et al. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998 (2001).
105. Jordan, R. et al. Inhibition of host ER glucosidase activity prevents Golgi processing of virion-associated bovine viral diarrhea virus E2 glycoproteins and reduces infectivity of secreted Virions. Virology 295, 10-19 (2002).
106. Wu, S. F. et al. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76, 3596-3604 (2002).
107. Block, T. M. & Jordan, R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antiviral Chem. Chemother. 12, 317-325 (2001).
108. Mottola, G. et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology 293, 31-43 (2002).
109. Schmidt-Mende, J. et al. Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 276, 44052-44063 (2001).
110. Brass, V. et al. An amino-terminal amphipathic α-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 277, 8130-8139 (2002).
111. Wolk, B. et al. Subcellular localization, stability, and transcleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74, 2293-2304 (2000).
112. Harada, T., Tautz, N. & Thiel, H. J. E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J. Virol. 74, 9498-9506 (2000).
113. Griffin, S. Hexamerization of the hepatitis C Virus p7 protein: possible fuction as a virus-encoded cation channel. 9th International Meeting on Hepatitis and Related Viruses, San Diego, USA (2002).
114. Hannon, G. J. RNA interference. Nature 418, 244-251 (2002).
115. Zamore, P. D. Ancient pathways programmed by small RNAs. Science 296, 1265-1269 (2002).
116. Novina, C. D. et al. siRNA-directed inhibition of HIV-1 infection. Nature Med. 8, 681-686 (2002).
117. Lee, N. S. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnol. 20, 500-505 (2002).
118. Jacque, J. M., Triques, K. & Stevenson, M. Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438 (2002).
119. Gitlin, L., Karelsky, S. & Andino, R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418, 430-434 (2002).
120. McCaffrey, A. P. et al. Gene expression - RNA interference in adult mice. Nature 418, 38-39 (2002).
121. Nelson, D. R., Lauwers, G. Y., Lau, J. Y. N. & Davis, G. L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118, 655-660 (2000).
122. Muratori, L. & Gibellini, D. A new route to apoptosis in hepatitis C virus infection. J. Hepatol. 35, 814-815 (2001).
123. Tsantrizos, Y. S. et al. Macrocyclic peptides active against the hepatitis C virus. Int. Patent Appl. WO 00/59929 (2000).
124. Kim, J. L. et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 6, 89-100 (1998).
125. Hashimoto, H. et al. Preparation of heterocyclic compounds as remedies for hepatitis C. Int. Patent Appl. WO 01/47883 (2001).